title: Melanoma driver mutations and immune therapy.
abstract: Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations' impact on immunotherapy outcomes is unclear. We assessed 229 patients treated with immunotherapy, and found that clinical outcomes were largely superior in those with NRAS mutations. Herein, we discuss our findings and their implications for melanoma therapeutics.
authors.affiliation: Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN; These authors contributed equally.
authors.forename: Douglas B
authors.initials: DB
authors.lastname: Johnson
authors.affiliation: Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN; These authors contributed equally.
authors.forename: Christine M
authors.initials: CM
authors.lastname: Lovly
authors.affiliation: Massachusetts General Hospital , Boston, MA.
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Sullivan
authors.affiliation: Columbia University Medical Center , New York, NY.
authors.forename: Richard D
authors.initials: RD
authors.lastname: Carvajal
authors.affiliation: Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center , Nashville, TN.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Sosman